Show simple item record

FieldValueLanguage
dc.contributor.authorHenson, Jeremy D
dc.contributor.authorVitetta, Luis
dc.contributor.authorQuezada, Michelle
dc.contributor.authorHall, Sean
dc.date.accessioned2022-08-24T05:09:17Z
dc.date.available2022-08-24T05:09:17Z
dc.date.issued2021en
dc.identifier.urihttps://hdl.handle.net/2123/29459
dc.description.abstractThe stress response is a well-defined physiological function activated frequently by life events. However, sometimes the stress response can be inappropriate, excessive, or prolonged; in which case, it can hinder rather than help in coping with the stressor, impair normal functioning, and increase the risk of somatic and mental health disorders. There is a need for a more effective and safe pharmacological treatment that can dampen maladaptive stress responses. The endocannabinoid system is one of the main regulators of the stress response. A basal endocannabinoid tone inhibits the stress response, modulation of this tone permits/curtails an active stress response, and chronic deficiency in the endocannabinoid tone is associated with the pathological complications of chronic stress. Cannabidiol is a safe exogenous cannabinoid enhancer of the endocannabinoid system that could be a useful treatment for stress. There have been seven double-blind placebo controlled clinical trials of CBD for stress on a combined total of 232 participants and one partially controlled study on 120 participants. All showed that CBD was effective in significantly reducing the stress response and was non-inferior to pharmaceutical comparators, when included. The clinical trial results are supported by the established mechanisms of action of CBD (including increased N-arachidonylethanolamine levels) and extensive real-world and preclinical evidence of the effectiveness of CBD for treating stress.en
dc.language.isoenen
dc.publisherMDPIen
dc.relation.ispartofJournal of Clinical Medicineen
dc.rightsCreative Commons Attribution 4.0en
dc.subjectAEAen
dc.subjectCBDen
dc.subjectN-arachidonylethanolamineen
dc.subjectcannabidiolen
dc.subjectendocannabinoiden
dc.subjecthypothalamus–pituitary–adrenal axis;en
dc.subjectstressen
dc.titleEnhancing Endocannabinoid Control of Stress with Cannabidiol.en
dc.typeArticleen
dc.subject.asrc0304 Medicinal and Biomolecular Chemistryen
dc.identifier.doi10.3390/jcm10245852
dc.type.pubtypePublisher's versionen
usyd.facultySeS faculties schools::Faculty of Medicine and Health::The University of Sydney School of Pharmacyen
usyd.citation.volume10en
usyd.citation.issue24en
usyd.citation.spage5852en
workflow.metadata.onlyNoen


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.